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Background: Randomized trials comparing outcomes after implantation of first generation drug-eluting stents (DES) versus second generation DES 
in small coronary arteries are limited. Stenting of small vessels might be associated with higher rates of adverse events. In a substudy of the SORT 
OUT IV trial, we assessed the impact of vessel size on clinical outcome among patients treated with everolimus-eluting stents (EES) or sirolimus-
eluting stents (SES).
Methods: “All-comer” patients (n=2,774) were randomized to EES and SES. Post hoc stratified analysis of clinical outcome at 18 months was 
performed for vessels with reference diameter ≤2.75 mm (small) versus >2.75 mm (large). The composite endpoint was major adverse cardiac 
events (MACE), defined as a composite of cardiac death, myocardial infarction (MI), stent thrombosis, or target vessel revascularization.
Results: Of 2,774 patients, 162 EES treated patients with 175 lesions and 189 SES treated patients with 213 lesions had only small vessels 
treated. 1,111 EES treated patients with 1,358 lesions and 1,068 patients with 1,266 lesions had only large vessels treated. MACE did not differ 
among patients with small vessels compared to patients with large vessels: 7.1% vs. 7.1%, Hazard Ratio (HR) 1.00, 95 % confidence interval (CI) 
0.66-1.53. Definite stent thrombosis was seen more often in patients with small vessels 1.1% vs. 0.3% (HR 3.56, 95% CI 1.04-12.2) compared to 
large vessels. In patients with lesions in small vessels, outcomes in EES treated patients did not differ significantly to SES treated patients; MACE 
6.2% vs. 8.0% (HR 0.77, 95% CI 0.34-1.71), cardiac death 0.6% vs. 1.1% (HR 0.58, 95% CI 0.05-6.44), MI 1.2% vs. 4.8% (HR 0.26, 95% CI 0.06-
1.28), and TLR 1.2% vs. 4.2%, (HR 0.29, 95% CI 0.06-1.35). Definite stent thrombosis was not seen in patients with small vessels treated with EES 
compared to 4 patients treated with SES.
Conclusions: Stent thrombosis, but not overall MACE, was seen more frequently in patient with small vessels. We found no significant differences 
between EES and SES in small vessels although the HRs was in favor of EES for all endpoints. Definite stent thrombosis was not seen among patients 
with small vessels treated with EES.
